Display options
Cite
Weston PS, Paterson RW, Modat M, et al. Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimers Dement (Amst). 2015;1(4):440-446doi: 10.1016/j.dadm.2015.10.001.
Weston, P. S., Paterson, R. W., Modat, M., Burgos, N., Cardoso, M. J., Magdalinou, N., Lehmann, M., Dickson, J. C., Barnes, A., Bomanji, J. B., Kayani, I., Cash, D. M., Ourselin, S., Toombs, J., Lunn, M. P., Mummery, C. J., Warren, J. D., Rossor, M. N., Fox, N. C., Zetterberg, H., & Schott, J. M. (2015). Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's & dementia (Amsterdam, Netherlands), 1(4), 440-446. https://doi.org/10.1016/j.dadm.2015.10.001
Weston, Philip S J, et al. "Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 1,4 (2015): 440-446. doi: https://doi.org/10.1016/j.dadm.2015.10.001
Weston PS, Paterson RW, Modat M, Burgos N, Cardoso MJ, Magdalinou N, Lehmann M, Dickson JC, Barnes A, Bomanji JB, Kayani I, Cash DM, Ourselin S, Toombs J, Lunn MP, Mummery CJ, Warren JD, Rossor MN, Fox NC, Zetterberg H, Schott JM. Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimers Dement (Amst). 2015 Nov 02;1(4):440-446. doi: 10.1016/j.dadm.2015.10.001. eCollection 2015 Dec. PMID: 26835507; PMCID: PMC4691234.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (Amst). 2015 Nov 02;1(4):440-446. doi: 10.1016/j.dadm.2015.10.001. eCollection 2015 Dec.

Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes.

Alzheimer's & dementia (Amsterdam, Netherlands)

Philip S J Weston, Ross W Paterson, Marc Modat, Ninon Burgos, Manuel J Cardoso, Nadia Magdalinou, Manja Lehmann, John C Dickson, Anna Barnes, Jamshed B Bomanji, Irfan Kayani, David M Cash, Sebastien Ourselin, Jamie Toombs, Michael P Lunn, Catherine J Mummery, Jason D Warren, Martin N Rossor, Nick C Fox, Henrik Zetterberg, Jonathan M Schott

Affiliations

  1. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
  2. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; Transitional Imaging Group, Centre for Medical Image Computing, University College London, London, UK.
  3. Transitional Imaging Group, Centre for Medical Image Computing, University College London, London, UK.
  4. Reta Lila Weston Institute of Neurological Studies, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
  5. Institute of Nuclear Medicine, University College London Hospitals, London, UK.
  6. MRC Centre for Neuromuscular Disease, Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK.
  7. MRC Centre for Neuromuscular Disease, Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

PMID: 26835507 PMCID: PMC4691234 DOI: 10.1016/j.dadm.2015.10.001

Abstract

INTRODUCTION: We aimed to assess the feasibility of determining Alzheimer's disease cerebrospinal fluid (CSF) cut points in small samples through comparison with amyloid positron emission tomography (PET).

METHODS: Twenty-three individuals (19 patients, four controls) had CSF measures of amyloid beta (Aβ)

RESULTS: Seventeen of 23 were amyloid-positive on visual reads, and 14 of 23 at an SUVR of ≥1.1. There was concordance (positive/negative on both measures) in 20 of 23, of whom 19 of 20 were correctly classified at an Aβ

DISCUSSION: Comparing amyloid PET and CSF biomarkers provides a means of assessing CSF cut points in vivo, and can be applied to small sample sizes. CSF tau/Aβ

Keywords: Amyloid PET; Aβ; Cerebrospinal fluid; Cut points; Diagnosis; Phosphorylated tau; Tau

References

  1. Arch Neurol. 2007 Mar;64(3):343-9 - PubMed
  2. J Nucl Med. 2012 Mar;53(3):378-84 - PubMed
  3. Alzheimers Dement. 2013 May;9(3):251-61 - PubMed
  4. JAMA Neurol. 2015 May;72 (5):571-81 - PubMed
  5. Ann Neurol. 2010 Dec;68(6):825-34 - PubMed
  6. Med Image Comput Comput Assist Interv. 2012;15(Pt 2):262-70 - PubMed
  7. Curr Alzheimer Res. 2011 May;8(3):266-72 - PubMed
  8. Lancet Neurol. 2014 Jun;13(6):614-29 - PubMed
  9. Brain. 2015 May;138(Pt 5):1327-38 - PubMed
  10. Lancet Neurol. 2003 Oct;2(10):605-13 - PubMed
  11. Alzheimers Dement. 2015 Aug;11(8):964-74 - PubMed
  12. Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1447-58 - PubMed
  13. J Neurol. 2015 Dec;262(12):2722-30 - PubMed
  14. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  15. JAMA Neurol. 2014 Oct;71(10 ):1282-9 - PubMed
  16. Brain. 2015 Jul;138(Pt 7):2020-33 - PubMed
  17. Dement Geriatr Cogn Disord. 2013;36(3-4):242-50 - PubMed
  18. Ann Neurol. 2013 Dec;74(6):826-36 - PubMed
  19. J Alzheimers Dis. 2014;41(3):801-7 - PubMed
  20. Biomark Med. 2012 Aug;6(4):391-400 - PubMed
  21. Alzheimers Dement. 2014 Nov;10(6):713-723.e2 - PubMed
  22. Lancet Neurol. 2012 Feb;11(2):170-8 - PubMed
  23. Brain. 2015 Mar;138(Pt 3):772-83 - PubMed
  24. Neurology. 1995 Mar;45(3 Pt 1):461-6 - PubMed
  25. Alzheimers Dement. 2015 Aug;11(8):986-93 - PubMed
  26. JAMA. 2011 Jan 19;305(3):275-83 - PubMed
  27. Alzheimers Dement. 2012 Jan;8(1):65-73 - PubMed
  28. J Alzheimers Dis. 2013;36(4):759-67 - PubMed

Publication Types

Grant support